We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Using AI technology to help the elderly feel safer and more comfortable in their homes. miicare has developed wearable devices and wireless sensors to monitor body vitals. If any irregularity occurs a call will be placed to a family member, a social worker, or a 24/7 professional telecare service. This increases support for the elderly and peace of mind knowing an emergency can be easily and quickly addressed. All data is secured using blockchain encryption.
days to go: Expired investment: £321,920
Qure’s aim is to provide individual healthcare that is both affordable and highly convenient, becoming the platform of choice for both patients and practitioners. Qure offer 24/7 private healthcare, without the huge price tag that is usually associated with these kinds of services. 
days to go: Expired investment: £1,162,206
Improving the railway construction industry by collecting data to reduce inefficiencies and overspending. Rail Diary is a B2B SaaS product that is designed to analyse information on infrastructure projects to improve particular elements that plague the industry. These include the delivery, commercialisation and the health and safety of projects. Rail Diary allows developers to monitor ongoing costs, forecast for the future and reduce the number of claims made. Rail Diary will generate revenue via a monthly subscription model ranging from £45 to £150, plus project fees.
days to go: Expired investment: £50,544
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.

Pitch Rated

61%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £376,230
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly. 
days to go: Expired investment: £116,960
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Glovebox Direct is an online automotive parts, accessories and merchandise marketplace selling original equipment direct from the car and bike brands.
days to go: Expired investment: £181,670
Viritech is a clean technology engineering company that is using F1-derived engineering to develop hydrogen powertrain solutions and related technologies for the automotive, aerospace, marine and distributed power industries. Viritech asserts that the Hydrogen Council forecasts that hydrogen will meet 18% of global energy demand by 2050. It aims to capture this demand through its technologies. Viritech argues that its location in MIRA Technology Park allows it access to R&D facilities used by many of the world's major automotive manufacturers, allowing it to scale its resources to meet the demands of every type of project. Viritech will use the investment to produce test hydrogen tanks, build the Apricale hypercar, complete designs for a Heavy Goods Vehicle (HGV), Sport Utility Vehicle (SUV) and a power generator, plan a larger raise and listing on AQuis Stock Exchange (AQSE) in 2022, and eventually commercialise its technology with its partner.
days to go: Expired investment: £726,807
Trecento Diagnostics, with the help of a molecular testing system complete, they are now ready to launch a patent-pending collection device named HygieCatch®. It is a non-invasive, needle-free examination, in the vet practice providing DNA extraction from urine onsite with a report within 40 minutes of extraction of the sample. The company has identified partners in the UAE and US and is also in early-stage discussions with UK vet practices.  Furthermore, for the purpose of commercialisation of HygieCatch & the technology used, alongside addition of new tests including Lyme disease the company is planning to raise its capital.  
days to go: Expired investment: £167,910
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go: Expired investment: £250,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph